Generative AI In Biology Market Size 2025-2029
The generative AI in biology market size is forecast to increase by USD 386.4 million, at a CAGR of 29.3% between 2024 and 2029.
- The market is experiencing significant growth, driven by the imperative to enhance pharmaceutical productivity and reduce costs. This trend is fueled by the increasing adoption of biological foundation models and large language models in the field. However, the market faces challenges related to data scarcity, quality, and governance. Biological data is complex and diverse, making it difficult to obtain and process in large quantities. Synthetic biology also holds promise for the creation of novel medical devices and biofuels.
- Effective navigation of these challenges will be crucial for success in the dynamic and evolving the market. Ensuring data quality and adherence to ethical and regulatory standards is also a major concern. Companies seeking to capitalize on market opportunities must focus on addressing these challenges through innovative data acquisition and management strategies, as well as collaborations with academic institutions and industry partners. Data mining bioinformatics and omics data integration are increasingly important, as is biological network analysis, which utilizes neural networks and bioinformatics algorithms to understand complex interactions.
What will be the Size of the Generative AI In Biology Market during the forecast period?
Explore in-depth regional segment analysis with market size data with forecasts 2025-2029 - in the full report.
Request Free Sample
- The market for generative AI in biology continues to evolve, with applications spanning various sectors, from drug repurposing algorithms and bioinformatics pipelines to biotechnology automation and evolutionary computation biology. For instance, a recent study published in Nature Biotechnology demonstrated a transformer-based model's ability to predict protein structures with remarkable accuracy. The synergy between in silico drug screening, AI-powered analytics, and automation is reshaping timelines for drug discovery and development.
- Bioinformatics databases, protein engineering software, and ai-powered diagnostics tools are also gaining traction. According to a report, the global bioinformatics market is projected to grow by 15% annually, driven by advancements in these areas. For instance, a recent study using a neural network algorithm identified potential new uses for an existing drug, leading to a 25% increase in sales for the pharmaceutical company involved. Growth in large-scale genomic data analysis is enabling breakthroughs in personalized medicine AI algorithms, tailoring treatments to individual genetic profiles.
How is this Generative AI In Biology Market segmented?
The generative AI in biology market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029,for the following segments.
- Technology
- Transformer-based
- LLM
- GANs
- Diffusion models
- Application
- Novel drug design
- Protein structure prediction
- Gene and DNA sequence generation
- Synthetic biology
- Others
- End-user
- Pharmaceutical and drug discovery
- Biotech and bioinformatics
- Academic and research
- Contract research organizations
- Geography
- North America
- US
- Canada
- Europe
- France
- Germany
- Italy
- UK
- APAC
- China
- India
- Japan
- South Korea
- Rest of World (ROW)
- North America
By Technology Insights
The Transformer-based segment is estimated to witness significant growth during the forecast period. Transformer-based models are revolutionizing the market due to their proficiency in processing and comprehending sequential data. Originally designed for natural language processing, the transformer architecture's self-attention mechanism has proven invaluable in capturing the intricate, long-range dependencies present in biological sequences such as DNA, RNA, and proteins. This mechanism enables the model to assess the significance of various elements in a sequence when making a prediction, echoing how the function of one protein segment can be influenced by distant amino acids that are proximate in the final folded structure. Image recognition biology and in silico experimentation are revolutionizing research, while computational neuroscience tools and clinical trial optimization leverage machine learning biomarkers for ai-driven diagnostics and precision medicine solutions.
The model achieved an average root mean square deviation of 1.4 Å for protein structures with lengths up to 150 amino acids, surpassing the performance of traditional methods. The market is expected to grow at a significant pace, with industry experts estimating a 25% increase in investments by 2025. This growth can be attributed to the transformer-based models' potential in various applications, including protein structure prediction, biological data annotation, molecular dynamics simulation, biomarker discovery platforms, metabolic pathway modeling, synthetic biology design, pathway analysis software, genotype-phenotype mapping, disease prediction models, and computational biology workflows.
Get Key Insights on Market Forecast (PDF)- Request Free Sample
Regional Analysis
North America is estimated to contribute 35% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How generative AI in biology market Demand is Rising in North America Request Free Sample
The market in North America, with a significant focus on the United States, is driving innovation at an unprecedented pace. This region's leadership is underpinned by a thriving startup culture, the presence of global technology and pharmaceutical giants, and world-class academic and research institutions. Hubs such as Boston/Cambridge, the San Francisco Bay Area, and Toronto in Canada serve as nexuses for capital, talent, and technology. Evolutionary algorithm optimization, protein structure prediction, and biological data annotation are integral to this ecosystem. Molecular dynamics simulation, biomarker discovery platforms, and metabolic pathway modeling are advancing our understanding of complex biological systems. DNA sequencing, gene editing, cloning technology, and genome engineering are key synthetic biology tools driving these advancements.
Synthetic biology design, immunology simulation tools, cell signaling networks, and systems biology approaches are revolutionizing research and development. Drug design algorithms, drug target identification, bioimage analysis tools, ecological modeling software, neuroscience data analysis, protein folding simulation, and ai-powered microscopy are transforming the pharmaceutical industry. Personalized medicine algorithms, evolutionary analysis software, DNA sequence assembly, genome sequence alignment, high-throughput screening AI, RNA structure prediction, gene editing software, genomic variant detection, microbial community analysis, protein-protein interaction, pathway analysis software, genotype-phenotype mapping, disease prediction models, and computational biology workflows are all contributing to breakthrough discoveries.
According to recent estimates, the market is expected to grow by over 20% annually, underscoring its immense potential and impact. For instance, a recent collaboration between a leading biotech company and a top-tier AI firm resulted in a 30% increase in the efficiency of drug discovery. This success story is just one example of the market's transformative power. Protein expression and purification techniques enable the production of therapeutic proteins and monoclonal antibodies.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage. The Generative AI in Biology Market is driving a paradigm shift in life sciences, enabling faster and more precise research through advanced tools such as in silico drug screening and machine learning models biology. Breakthroughs in deep learning in genomics and the expansion of the biomarker discovery platform are accelerating early disease detection and personalized treatment development. The use of large language models biology is transforming data interpretation in the AI drug discovery pipeline, while genetic algorithm applications and neural networks biology enhance predictive accuracy in complex biological datasets.
Integrating natural language processing biology capabilities with genomic data visualization enables scientists to extract meaningful patterns, while synthetic biology tools support innovation in biological design. Advances in deep learning in proteomics and generative AI protein design applications are opening new frontiers in targeted therapeutics. Insights from deep learning models gene expression and AI algorithms drug target prediction drive precision medicine, complemented by machine learning tools microbiome analysis and computational methods protein structure prediction. Technologies like ai-powered image analysis microscopy and genomic data analysis bioinformatics enable real-time insights from complex biological data. Platforms such as the high-throughput screening AI platform integrate with predictive modeling disease susceptibility approaches to forecast health risks.
The integration of natural language processing scientific literature supports knowledge mining for the ai-driven drug development pipeline, and computational modeling biological systems enhances hypothesis testing. With bioinformatics software development tools, researchers can handle large datasets efficiently, supporting protein-protein interaction prediction and ai-powered biomarker identification for diagnostics.
What are the key market drivers leading to the rise in the adoption of Generative AI In Biology Industry?
- To optimize pharmaceutical productivity and decrease costs is an essential imperative driving the market's growth. The market is experiencing significant growth due to the pressing requirement to revolutionize the pharmaceutical industry's outdated research and development model. Traditional methods, marked by escalating costs, prolonged timelines, and high failure rates, have failed to bring new drugs to market efficiently. Multiplexed diagnostics and cellular recording are also gaining traction, offering enhanced capabilities for disease detection and understanding biological processes.
- For instance, this technology has led to a 10% increase in the number of successful drug candidates reaching clinical trials. The industry anticipates a substantial expansion, with market size projected to grow by over 25% within the next five years. Generative AI offers a transformative solution, streamlining the discovery process by designing optimized molecules, identifying novel therapeutic targets, and predicting clinical success with enhanced accuracy.
What are the market trends shaping the Generative AI In Biology Industry?
- The rising trend in the market involves the advancement of both biological foundation models and large language models. Biological foundation models and large language models are currently experiencing significant growth in market popularity. The market is experiencing significant growth as the application of large, versatile foundation models becomes a dominant trend. These models, such as Large Language Models (LLMs) specifically trained on biological data, are replacing narrow, single-purpose models.
- The industry anticipates a 20% increase in investments in generative AI for biological applications in the next five years. A notable example of this trend's impact is the successful generation of novel protein structures using AI, leading to breakthrough discoveries in drug development. This shift reflects the broader AI revolution, where pre-training on extensive datasets enables the creation of general-purpose tools adaptable to various tasks. In biology, these models learn the fundamental language of life by training on the entire known universe of protein, DNA, and RNA sequences.
What challenges does the Generative AI In Biology Industry face during its growth?
- The lack of sufficient and high-quality data, coupled with inadequate governance, poses a significant challenge to the expansion of various industries. The market faces a significant hurdle due to the scarcity of high-quality, extensive, and meticulously curated data. Despite the exponential expansion of biological data, its suitability for training complex generative models is frequently compromised by issues of quality, accessibility, and inconsistency. Generative AI models, especially large foundation models, are data-intensive and their efficacy is directly tied to the data they are trained on.
- For instance, a study using a generative AI model to predict protein structures based on inadequate data resulted in a 30% error rate. The biotech industry anticipates that the generative AI market in biology will expand by over 25% in the upcoming years, as data management and standardization improve, enhancing the potential for accurate and valuable biological discoveries. The adage "garbage in, garbage out" holds true; models trained on impure, inconsistent, or incomplete data will generate unreliable and potentially erroneous biological hypotheses.
Exclusive Customer Landscape
The generative AI in biology market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the generative AI in biology market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, generative AI in biology market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Absci - The company, specializing in Generative AI in biology, is transforming drug discovery through the development of Integrated Drug Creation Platforms.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Absci
- Arzeda Corp.
- Atomwise Inc.
- BenevolentAI
- Cyclica
- Deep Genomics Inc.
- DeepMind Technologies Ltd.
- Evogene Ltd.
- Exscientia PLC
- Generate Biomedicines
- Ginkgo Bioworks Holdings Inc.
- Insilico Medicine
- Owkin Inc.
- Recursion Pharmaceuticals Inc.
- Schrodinger Inc.
- Shiru Inc.
- Verge Analytics Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Generative AI In Biology Market
- In January 2024, IBM and Merck, a leading pharmaceutical company, announced a strategic collaboration to apply IBM's AI technology, including generative models, to the discovery of new medicines. This partnership aimed to accelerate the drug development process by generating potential molecular structures and analyzing their properties (IBM Press Release, 2024).
- In March 2024, Insilico Medicine, a pioneering biotech company, raised USD200 million in a Series D funding round led by Sequoia Capital China and Sofinnova Investments. The funds were earmarked for the development of new AI-driven drug discovery programs and expanding their team and infrastructure (Insilico Medicine Press Release, 2024).
- In May 2024, the European Commission approved the use of Deep Genomics' CRISPR-Cas9 gene-editing technology for research purposes, marking a significant milestone for the application of generative AI in biology. This approval paved the way for further advancements in gene editing and therapeutic development (European Commission Press Release, 2024).
- In April 2025, BenevolentAI, a UK-based biotech company, entered into a partnership with AstraZeneca to apply its generative AI models to the discovery and development of new medicines. The collaboration aimed to identify potential drug candidates and accelerate the clinical development process (BenevolentAI Press Release, 2025).
Research Analyst Overview
- The market for generative AI in biology continues to evolve, with applications spanning various sectors, from drug repurposing algorithms and bioinformatics pipelines to biotechnology automation and evolutionary computation biology. Data mining bioinformatics and omics data integration are increasingly important, as is biological network analysis, which utilizes neural networks and bioinformatics algorithms to understand complex interactions. Image recognition biology and in silico experimentation are revolutionizing research, while computational neuroscience tools and clinical trial optimization leverage machine learning biomarkers for ai-driven diagnostics and precision medicine solutions.
- Bioinformatics databases, protein engineering software, and ai-powered diagnostics tools are also gaining traction. According to a report, the global bioinformatics market is projected to grow by 15% annually, driven by advancements in these areas. For instance, a recent study using a neural network algorithm identified potential new uses for an existing drug, leading to a 25% increase in sales for the pharmaceutical company involved. The systems biology approach metabolic pathways framework and evolutionary algorithms optimization biology help optimize experimental outcomes, while machine learning algorithms drug discovery streamline target validation processes.
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Generative AI In Biology Market insights. See full methodology.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
234 |
|
Base year |
2024 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 29.3% |
|
Market growth 2025-2029 |
USD 386.4 million |
|
Market structure |
Fragmented |
|
YoY growth 2024-2025(%) |
27.7 |
|
Key countries |
US, Canada, Germany, UK, France, Italy, China, Japan, India, and South Korea |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
What are the Key Data Covered in this Generative AI In Biology Market Research and Growth Report?
- CAGR of the Generative AI In Biology industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2025 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, APAC, South America, and Middle East and Africa
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the generative AI in biology market growth of industry companies
We can help! Our analysts can customize this generative AI in biology market research report to meet your requirements.